Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (
NASDAQ: BIIB ) announced today, March 31, 2026, that it has entered into a definitive agreement to acquire Apellis Pharmaceuticals (
NASDAQ: APLS ) for approximately $5.6 billion in cash. The deal, valued at $41 per
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally In a significant milestone for precision medicine, Vertex Pharmaceuticals (
NASDAQ:VRTX ) emerged as the top performer in the S&P 500 on March 11, 2026, with its shares climbing 8.3%. The rally followed the release of highly encouraging clinical data and operational updates from its renal pipeline, specifically targeting
Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER trial. The data, which focused on povetacicept for the treatment of IgA nephropathy (IgAN), showcased a 52% reduction in proteinuria, a
Why Vera Therapeutics Stock Zoomed Higher Today The company has a fine chance of commercializing its leading investigational drug in the near future.
Why Vera Therapeutics Stock Rocked the Market on Tuesday A competitor recently earned FDA approval, but this drug is reportedly going to be pricey.
Why Vera Therapeutics Stock Crushed it Today If all goes well, the company will have a drug on the market that could bring in billions of dollars in revenue.
Get insights into the top gainers and losers of Tuesday's after-hours session. After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
VERA THERAPEUTICS INC (NASDAQ:VERA) Reports Q3 2025 Earnings, Misses EPS Estimates Amid Key Clinical Progress Vera Therapeutics posts Q3 2025 financial results with a widened loss, but key clinical progress for atacicept in IgAN and an upcoming BLA submission drive investor focus.
Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment.
